Peptides from Ovarian Tumors Induce Immune Responses
Author Information
Author(s): Gritzapis A D, Perez S A, Baxevanis C N, Papamichail M
Primary Institution: Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece
Hypothesis
Can unfractionated peptides from HER-2/neu-overexpressing ovarian tumors induce effective cytotoxic T lymphocyte (CTL) responses?
Conclusion
The study found that peptides from HER-2/neu-overexpressing ovarian tumors can effectively induce CTL responses that have potent antitumor effects.
Supporting Evidence
- Peptides from HER-2/neu-overexpressing tumors induced specific CTL responses.
- Adoptive transfer of CTLs significantly prolonged survival in SCID mice.
- ACE from HER-2/neu-overexpressing tumors was immunodominant.
Takeaway
Researchers found that proteins from certain ovarian tumors can help the body's immune system fight cancer better.
Methodology
The study involved isolating peptides from tumor cell extracts and using them to generate CTLs from patients' immune cells, which were then tested for their ability to kill tumor cells in vitro and in vivo.
Potential Biases
Potential bias due to the small sample size and the specific patient population studied.
Limitations
The study was limited to a small number of patients and did not explore the long-term effects of the treatment.
Participant Demographics
HLA-A2.1+ patients with histologically confirmed ovarian cancer, clinical stage III and IV.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website